SG Americas Securities LLC Purchases New Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

SG Americas Securities LLC purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,864 shares of the biopharmaceutical company’s stock, valued at approximately $705,000.

A number of other large investors have also modified their holdings of AGIO. Farallon Capital Management LLC grew its position in Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after buying an additional 63,900 shares during the period. Vanguard Group Inc. increased its stake in Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock valued at $162,926,000 after purchasing an additional 44,583 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after acquiring an additional 388,381 shares during the period. Marshall Wace LLP grew its stake in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Agios Pharmaceuticals by 5.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,108,613 shares of the biopharmaceutical company’s stock worth $32,416,000 after acquiring an additional 62,153 shares during the last quarter.

Analysts Set New Price Targets

AGIO has been the subject of a number of research reports. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $52.20.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $42.65 on Monday. The stock has a fifty day moving average price of $44.59 and a two-hundred day moving average price of $40.66. Agios Pharmaceuticals, Inc. has a 1 year low of $19.80 and a 1 year high of $53.28. The firm has a market cap of $2.42 billion, a P/E ratio of -6.75 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. Agios Pharmaceuticals’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the company posted ($1.51) EPS. On average, research analysts predict that Agios Pharmaceuticals, Inc. will post -4.87 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.